All News

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

Cycling and mixed cycling were associated with a reduced risk of all-cause dementia, including of young onset, as well as increased hippocampal volume.

These 14 recommendations from the American College of Lifestyle Medicine comprise the core of the first-ever guideline centered on lifestyle change as a first-line intervention.

Valid and accessible measures are needed to monitor low-value care practices and set benchmarks for de-implementation efforts, researchers reported.

High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

Novel guidelines include specific strategies that support the prescription, implementation, and monitoring of lifestyle changes to reach glycemic control and, possibly, disease remission.

RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.